Berenberg Bank Remains a Buy on Sanofi (SNY), Sets a €118 Price Target
The rating followed the company's presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, highlighting various growth drivers within Specialty Care that bring an optimistic light to its operations.
Dozens of pharmaceutical capsules piled on top of one another to show the scale of the company's drug contributions to the industry.
Brian Foard, Head of Specialty Care at Sanofi (NASDAQ:SNY), stated that the product dupilumab is expected to undergo double-digit CAGR growth between 2023 and 2030, delivering an estimated EUR 22 billion by the end of the forecast period.
He said that Sanofi's (NASDAQ:SNY) recently launched assets, such as ALTUVIIIO and Qfitlia, further add to this positive outlook. This also includes SARCLISA, the first FDA-approved treatment for adults with newly diagnosed multiple myeloma, which is continuing to expand its indications from both oncology and multiple myeloma perspectives.
The company thus presented a growth story at the conference, including in neurology, where it anticipates a reentry into the MS space through the upcoming launch of tolebrutinib.
Sanofi (NASDAQ:SNY) ranks 11th on our list of the best drug stocks to buy according to hedge funds. It researches, produces, and distributes pharmaceutical products. The company's operations are divided into the Pharmaceuticals, Consumer Healthcare, and Vaccines segments.
While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hypebeast
25 minutes ago
- Hypebeast
Rimac Nevera R Sets 24 World Records and Reclaims 0–400–0 Title
Summary TheRimac Nevera Rhas shattered expectations by setting 24 new performance records, reclaiming the title for fastest 0–400–0 km/h time at 25.79 seconds, beating its predecessor by over four seconds. The track-dominating electric hypercar now holds the crown as the world's quickest accelerating production vehicle. Powered by a 2,107 hp quad-motor system and a recalibrated torque vectoring setup, the Nevera R hits 0–60 mph in just 1.66 seconds and tops out at 431.45 km/h (268.2 mph). Other benchmarks include 0–100 km/h in 1.72 seconds, 0–300 km/h in 7.89 seconds and a quarter-mile time of 7.90 seconds. Key upgrades include a re-engineered aerodynamic package with 15% more downforce, new Michelin Cup 2 tires and a 10% boost in aerodynamic efficiency. The Nevera R also introduces improved traction, cornering grip and braking power, showcased by its blistering 0–100–0 km/h stop in 3.32 seconds. The new record marks a major leap from the originalNevera, which previously held 23 records in a single day. Only 40 units of the Nevera R will be built, priced from €2.3m EUR ($2,689,335 USD). According to CEO Mate Rimac, 'Breaking records is in our DNA—and we won't stop here.' With Nürburgring and Goodwood benchmarks already in its crosshairs, the Nevera R is poised to dominate further.
Yahoo
25 minutes ago
- Yahoo
Domino's Pizza Announces Its Best Deal Ever for $9.99
Domino's Pizza, Inc. (NASDAQ:DPZ) is one of the . On July 7, Domino's Pizza, Inc. (NASDAQ:DPZ) announced that it is bringing back its 'Best Deal Ever' promotion! This deal will allow customers to enjoy any pizza with their favourite toppings for $9.99 when they order online between July 7 and August 8. This deal includes Domino's Hand Tossed, Handmade Pan, New York Style, Gluten Free, and Crunchy Thin Crust pizzas, as well as an assortment of sauces and toppings. This deal is a move for the company to gain traction and continue its long-standing legacy in the franchise food business. Jonathan Weiss/ Loop Capital retains its Buy rating on DPZ with a price target of $564. The firm remains positive on DPZ as Domino's same-store sales growth surpassed expectations in Q2. From March 23 to June 14, 2025, Domino's comparable sales soared over 2.5%, aligning with Loop Capital's estimates but exceeding the consensus of 1.9%. Domino's latest marketing deal will continue to have a positive impact on its sales during the current quarter. Domino's Pizza, Inc. (NASDAQ:DPZ) is a prominent pizza company with a significant business in both delivery and carryout. While we acknowledge the potential of DPZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
33 minutes ago
- Yahoo
BTIG Maintains a Buy Rating on Novavax (NVAX), Sets a $19 PT
Novavax Inc. (NASDAQ:NVAX) is one of the best cheap stocks with huge upside potential. On June 11, BTIG maintained a Buy rating on Novavax Inc. (NASDAQ:NVAX) with a $19 price target. A closeup of a vial of the biotechnology company's vaccines. BTIG analyst Thomas Shrader told investors following the company's announcement of the results of the initial cohort of its COVID-19-Influenza Combination and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza Phase 3 trial that the primary goal was to exhibit that the immunogenicity of both the COVID-19 and Influenza vaccines was within the protective range with 'interference' not being a strong factor. He stated that the first CIC data 'looks unremarkable – exactly what we hoped for,' adding that the 'most positive signs from today's data' were stronger immunogenicity for the Novavax flu vaccine for some antigens compared to the 'gold-standard' flu vaccine FLUZONE-HD. Novavax Inc. (NASDAQ:NVAX) is a biotechnology company that discovers, develops, and commercializes recombinant vaccines. While we acknowledge the potential of NVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
